Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials

Table 1 Characteristics of studies in meta-analysis

Trials	Treatment	Dialysis modality	Country	No. patients	Age,years	Mean Baseline SBP,mmHg	Mean Baseline DBP,mmHg	Residual GFR,mL/min per 1.73 m2	Kt/V	Mean Duration on dialysis,months	follow-up, years
ACE-Is vs. placebo
FOSIDIAL 2006 [9]	ACE-I/Placebo	HD	France	397	67	146	77		1.3	49.2	2
ARBs vs. placebo
SAFIR 2014 [11]	ARB/Placebo	HD	Denmark	82	61	146	76	5.2		4.6	1
ACE-Is vs. active control
Yilmaz 2010 [18]	ACE-I/CCB	HD	Turkey	92	53.8	157	88		1.4	47	1
Philip 2003 [14]	ACE-I/Conventional ahtihypertensive agents	PD	China Kong Hong	60	58	151	83.5	3.55	2.08	10.5	1
HDPAL 2014 [20]	ACE-I/atenolol	HD	USA	200	53.1	151	87.1				1
ARBs vs. active control
Suzuki 2008 [10]	ARB/Conventional ahtihypertensive agents	HD	Japan	366	59.5	155	81		1.1	44.4	3
Takahashi 2006 [8]	ARB/CCB	HD	Japan	80	61	153	82			33.1	1.6
OCTOPUS 2013 [19]	ARB/Conventional ahtihypertensive agents	HD	Japan	469	59	159	80		1.2	88	3.5
Suzuki 2004 [10]	ARB/CCB	PD	Japan	34	63.5	165	76	4.3	1.97		24
Wang J	ARB/Conventional ahtihypertensive agents	PD	China	32	42	158	102	4.8	2.09	29	2.4
Zhong H	ARB/CCB	PD	China	44	45	134	83	4.5	1.97		1

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; GFR, glomerular filtration rate; HD, hemodialysis; PD, peritoneal dialysis

ISSN: 1471-2369